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available and the future place of these drugs is diﬃ  cult 
to comprehend but future treatments of patients 
with indolent lymphomas will probably involve less 
chemotherapy and more biological agents and, for 
aggressive lymphomas, the combination of these 
new agents with chemotherapy might decrease the 
refractoriness to therapy identiﬁ ed in some patients.
Altogether, the results of Westin and colleagues 
strongly support the restoration of an antitumour 
response that is directly mediated by anti-PD1 antibodies. 
However, interplay between the micro environment and 
tumour cells in follicular lymphoma is highly complex 
and alternative pathways could not be deﬁ nitely ruled 
out by the correlative analyses. Further studies are thus 
needed to fully decipher the precise mechanism of 
pidilizumab action in lymphomas. The advantages or 
disadvantages of other anti-PD1 antibodies, nivolumab 
and lambrolizumab, or anti-PD-L1 antibodies compared 
with pidilizumab have yet to be described.
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Second-line chemotherapy for patients with 
oesophagogastric adenocarcinoma
During the past two decades, there have been 
major advancements in cancer treatment, such as 
the incorporation of newer cytotoxic, molecularly 
targeted, and other biological agents to traditional 
chemotherapy. Unfortunately, clinical trials involving 
novel agents have had little success in the treatment 
of oesophagogastric adenocarcinoma, which is one of 
the main causes of cancer-related deaths worldwide. 
Initial reports of chemotherapy regimens that include 
ﬂ uoropyrimidines, anthracyclines, or cisplatin provided 
evidence of a survival beneﬁ t, and, at present, 20 years’ 
worth of clinical trials have indicated ﬂ uoropyrimidines 
(ﬂ uorouracil or its oral pro-drugs) and platinum 
combination, with or without the addition of anthra-
cyclines, as the standard for ﬁ rst-line treatment. A 
small subset of patients with HER2-positive disease 
might beneﬁ t from trastuzumab,1 but more than half 
of patients do not respond to ﬁ rst-line chemotherapy, 
and even in those who respond, the duration of 
response is as short as a few months. Due to the 
absence of evidence associated with the beneﬁ t of 
second-line chemotherapy, and the potential for 
toxicity from such treatment, the proportion of 
patients oﬀ ered further therapy varies from 20% to 
50%, depending on the region.2
In the past 4 years, the results of three multicentre 
phase 3 trials assessing the role of second-line 
chemotherapy in patients with oesophagogastric 
adenocarcinoma have been reported.3–5 Findings 
from all three trials showed signiﬁ cant reductions in 
the risk of death—reductions in all three trials were 
of a similar magnitude, which gives an indication 
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of the robustness of these ﬁ ndings because the 
investigators tested diﬀ erent chemotherapeutic 
regimens in patients of diﬀ erent ethnic origins. The 
ﬁ rst trial included 40 pretreated patients who received 
either irinotecan (in the experimental group) or best 
supportive care (in the control group).3 The second trial 
compared salvage chemotherapy with best supportive 
care in 202 Korean patients with gastric cancer.4 The 
study was designed to include patients who were 
pretreated with not one but two prior chemotherapy 
regimens, a factor that might have diluted the results. 
The investigators reported a signiﬁ cant survival 
beneﬁ t with chemotherapy versus best supportive care 
(5·3 months with chemotherapy vs 3·8 months with 
best supportive care; hazard ratio [HR] 0·657, 95% CI 
0·485–0·891).
In The Lancet Oncology, Hugo Ford and colleagues5 
present ﬁ ndings from the third of these trials, 
the COUGAR-02 trial. The researchers recruited 
168 patients with oesophagogastric adenocarcinoma 
refractory to the ﬁ rst-line combination of a 
ﬂ uoropyrimidine and a platinum-based agent. 
Patients, who had an Eastern Cooperative Oncology 
Group performance score of 0–2, were randomly 
allocated to receive docetaxel 75 mg/m² every 
3 weeks plus active symptom control (n=84), or active 
symptom control alone (n=84). The results showed 
that second-line docetaxel improved median overall 
survival compared with active symptom control alone 
(5·2 months [95% CI 4·1–5·9] vs 3·6 months [3·3–4·4]; 
HR 0·67, 95% CI 0·49–0·92; p=0·01). Global health-
related quality of life was similar in the two groups, 
and disease-speciﬁ c health-related quality-of-life 
measures also showed that second-line treatment 
reduced dysphagia and abdominal pain.
We should consider several issues raised by the 
results of COUGAR-02 and previous trials. These trials 
ﬁ rmly establish the role of second-line chemotherapy 
in patients with oesophagogastric adenocarcinoma. 
Any oncologists who do not recommend further 
treatment in this setting should change their care 
of patients with pretreated oesophagogastric 
adenocarcinoma immediately. Obviously, patients who 
failed or were refractory to ﬁ rst-line chemotherapy 
with ﬂ uoropyrimidines and platinum should receive 
second-line treatment, with best supportive care 
reserved for those with a poor performance status. 
We should also ask whether the use of single-agent 
docetaxel (or irinotecan) is now a standard of care in 
the second-line setting. We should decide if the next 
step should be phase 3 trials comparing other agents 
or combinations with docetaxel. While seeking the 
answers to these questions, we should remember 
that the role of chemotherapy in this setting remains 
strictly palliative, in terms of its ability to substantially 
improve overall survival and to maintain patients’ 
quality of life. 
Despite the failures of several clinical trials involving 
molecularly targeted agents, the phase 3 REGARD 
trial of ramucirumab, a monoclonal antibody against 
VEGFR, was successful.6 In this trial, pretreated 
patients with oesophagogastric adenocarcinoma were 
randomly allocated to receive ramucirumab or placebo 
as second-line treatment. Surprisingly, the survival 
beneﬁ t achieved with ramucirumab (3·8 months 
with placebo vs 5·2 months with ramucirumab; 
HR 0·776, 0·603–0·998) was similar to that seen in 
the COUGAR-02 trial. The results of the more clinically 
relevant RAINBOW trial (NCT001170663), which 
assessed the addition of ramucirumab to paclitaxel 
versus paclitaxel alone for second-line therapy, are 
expected in the near future.
The COUGAR-02 investigators should be 
commended for doing this trial—their ﬁ ndings seem 
to end the debate about the beneﬁ ts of second-
line chemotherapy in patients with advanced oeso-
phago gastric adenocarcinoma. However, in the real 
world—outside of the strict enrolment criteria of 
a clinical trial—many patients develop peritoneal 
carcinomatosis during the course of their disease, 
leading to a rapid symptomatic deterioration and 
chemotherapy intolerance.2 Data from COUGAR-02 
and other trials should be interpreted carefully because 
of the potential selection bias—only a small subset of 
patients continue to have a good performance status 
after ﬁ rst-line failure and are still physically ﬁ t enough 
to be oﬀ ered second-line chemotherapy. Nevertheless, 
the meticulous eﬀ orts of these and other researchers 
have brought us into the molecular era of cancer 
treatment. Better molecular characterisation of cancer 
has brought hope for more successful treatment,1,6 
including the use of trastuzumab for patients with 
HER2-positive disease and hopefully ramucirumab in 
the second-line setting. Experience with other types of 
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cancer has taught us that a substantial improvement 
in the treatment of oesophagogastric adenocarcinoma 
might be achieved with individualised treatment 
strategies, including the identiﬁ cation of genetic 
alterations and studying of the molecular biology of 
therapeutic agents.
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Eﬀ ects of histone deacetylase inhibitors on alloresponses 
Inhibition of histone deacetylases (HDACs) can have 
important antineoplastic eﬀ ects through cytotoxic 
and pro apoptotic mechanisms, and it can prevent 
cell pro liferation and promote cell diﬀ erentiation. 
Vorinostat, an inhibitor of both class I and II HDACs, 
and romidepsin, an inhibitor of class I HDACs only, 
are clinically approved in the USA for treatment 
of cutaneous T-cell lymphoma. In The Lancet 
Oncology, Sung Won Choi and colleagues report a 
phase 1/2 study of additional mechanisms of action of 
vorinostat.1
The researchers added vorinostat to a standard 
regimen of tacrolimus and mycophenolate mofetil for 
pro phylaxis of acute graft-versus-host disease (GVHD) 
in patients receiving reduced-intensity conditioning 
and an allogeneic haemopoietic stem-cell transplant. 
Addition of vorinostat proved safe, with the most 
frequent adverse events being electrolyte disturbances 
and hyperglycaemia. The cumulative incidence of 
acute GVHD was 22% (95% CI 13–36) by day 100 
after haemopoietic stem-cell transplantation. The 
results raise several questions: what mechanisms are 
involved? How might this therapeutic approach be 
optimised further? What steps will be necessary for 
wider clinical application? 
Acute GVHD is dependent on activation and 
proliferation of alloreactive T cells. Although inhibitors 
of HDACs aﬀ ect many cell types, their potent 
inhibitory eﬀ ects on T-cell responses2 are especially 
relevant. HDAC inhibitors such as vorinostat have 
inhibitory eﬀ ects on T-cell activation, diﬀ erentiation, 
and eﬀ ector functions, but the eﬀ ects on normal T-cell 
development are much diminished. In a fully MHC-
mismatched model of GVHD,3 vorinostat reduced 
inﬂ ammation and GVHD-dependent mortality by 
targeting activated allospeciﬁ c T cells but did not 
aﬀ ect broad donor T-cell expansion and immune 
reconstitution.3 Likewise, in a murine model, 
vorinostat lowered the incidence and severity of 
GVHD while preserving the graft-versus-leukaemia 
eﬀ ect.4 The study by Choi and colleagues is notable 
because the data show the ability of HDAC inhibitors 
to dampen undesired T-cell alloreactivity after 
haemopoietic stem-cell transplantation without 
aﬀ ecting engraftment or promoting relapse or 
increased rates of fungal or other infections. 
Although the precise mechanisms underlying 
the immunosuppressive and anti-inﬂ ammatory 
actions of HDAC inhibitors might vary by cell type 
and context, one unifying theme that has arisen 
from experimental and in-vitro studies with human 
cells is that inhibition of HDAC activity can promote 
development and suppressive functions of FOXP3+ 
T-regulatory (Treg) cells.5 After 2 weeks of treatment 
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